Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.

Context Therapeutics, a US-based developer of treatments for cancers affecting women based on research at Drexel University, has filed for an initial public offering that could raise up to $21m. The company will issue 1.5 million shares and has set a price range of $12 to $14. It aims to list on Nasdaq Capital Market…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.